Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

← catalyst calendar

NCT05134441 · readout ≤ 103 d

Sponsored by Immunic AG (industry) · IMUX — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

1,121actual

Sites

Countries

Albania, Algeria, Bulgaria +13

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-11-18

actual

When the study began enrolling

Primary completion

Nov 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Sep 2033

estimated

The whole study's end, after follow-up

First posted

2021-11-26

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-02-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Multiple Sclerosis

Interventions

Drug: IMU-838 tablets — also filed as vidofludimus calcium
Drug: Placebo matching IMU-838 tablets — also filed as Placebo matching vidofludimus calcium

Primary outcome

what the primary-completion date above is the date OF

To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse

measured 72 weeks

Publications

PMID 41933619 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · IMUX's whole pipeline · Catalyst calendar · Every registered study · What changed